Exploring and bypassing resistance to targeted therapies in colorectal cancer.

Saved in:
Bibliographic Details
Title: Exploring and bypassing resistance to targeted therapies in colorectal cancer.
Authors: Favier S; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France., Xiong W; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France., Chalabi-Dchar M; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France., Chettab K; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France; Hospices Civils de Lyon, Lyon, France., Piercey O; Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia; Peter MacCallum Cancer Centre, Department of Medical Oncology, Melbourne, Victoria, Australia., Wu T; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France., Fenouil T; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France; Hospices Civils de Lyon, Lyon, France., Albaret MA; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France., Jordheim LP; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France., Diaz JJ; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France., Hollande F; Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia; Collaborative Centre for Genomic Cancer Medicine, University of Melbourne, Melbourne, Victoria, Australia; Plasticity, Heterogeneity and Tumour Microenvironment International Research (PHANTOM) Laboratory, CNRS and The University of Melbourne, , Melbourne, Victoria, Australia., Dumontet C; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France; Hospices Civils de Lyon, Lyon, France., Mertani HC; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon, Centre Léon Bérard, Lyon CEDEX 08, France; Plasticity, Heterogeneity and Tumour Microenvironment International Research (PHANTOM) Laboratory, CNRS and The University of Melbourne, , Melbourne, Victoria, Australia. Electronic address: hichem.mertani@lyon.unicancer.fr.
Source: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2025 Dec; Vol. 193, pp. 118741. Date of Electronic Publication: 2025 Nov 11.
Publication Type: Journal Article; Review
Journal Info: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1950-6007
DOI:10.1016/j.biopha.2025.118741